a federal advisory panel recommended friday food drug administration reject proposal undertake groundbreaking ussoviet study 20000 women determine whether hormonal drug prevent breast cancer the fdas oncology drugs advisory committee agreed longterm study conducted determine effect hormonal drug tamoxifen preventing breast cancer cancers healthy women but panel said members concluded design proposed 10year $ 100million study women united states soviet union flawed the committee said would recommend ways correct deficiencies im disappointed women country said phillip d bretz director desert breast institute rancho mirage one proposed study leaders i felt time none answers going resolved study done although recommendation fda advisory committee binding typically wields considerable weight agency decisionmaking the fda must approve us segment study begin the committee said insufficient information study would conducted including recruitment patients handling data some members also expressed concern volunteers would high enough risk breast cancer bretz however said study rejected academic ties traditional researchers he said would revise study proposal effort satisfy committees demands the proposed study endorsed american soviet cancer specialists march would involve administration tamoxifen antiestrogen drug already widely used postsurgical breast cancer therapy women considered high risk breast cancer it would first largescale study undertaken jointly united states soviet union sponsors said the pool participants 10000 country would consist primarily daughters sisters mothers women breast cancer considered high risk developing disease half women would given medically worthless placebo comparison purposes the researchers predicted 25 reduction incidence breast cancer among women given drug the study would coordinated bretz dr philip b dreisbach eisenhower medical center rancho mirage dr david zaridze deputy director allunion cancer research institute moscow the study opposed womens health advocacy groups said dangerous experiment drugs healthy women this drug riskfree said cindy pearson program director national womens health network its fine drug breast cancer patient woman facing possibility death willing take drug risk but jump drug thats effective group lifethreatening disease huge trial healthy women crazy but dr wendy schain psychologist memorial cancer institute long beach former breast cancer patient recommended approval study this best weve got said we need get answers we better way get tamoxifen causes cancer animals linked stroke heart disease endometrial cancer women according fda sponsors proposed study however maintain tamoxifen minimal negative side effects often reduces cholesterol eases cardiovascular problems fda officials said large study drug healthy humans little unusual unprecedented any time study drug prophylaxis prevention youre going use healthy people said dr robert temple fdas director new drug evaluation tamoxifen manufactured british firm imperial chemical industries sold brand name nolvadex used decade prevent recurrence tumors women whose cancer spread underarm lymph nodes recently fda approved use postsurgical treatment early breast cancer women node involvement in country produced marketed ici pharmaceuticals wilmington del tamoxifen works blocking socalled estrogen receptors areas surface cells hormone binds exert effects in way blocks effects estrogen believed play role stimulation tumor growth breast cancer breast cancer common malignancy among women united states second leading cause cancer death among women lung cancer an estimated 150000 new cases diagnosed year